Navigation Links
Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
Date:8/26/2008

SEATTLE, Aug. 26 /PRNewswire/ -- Omeros Corporation today announced the publication of the results from a Phase 1/Phase 2 trial investigating OMS103HP in arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is designed to improve postoperative knee function and motion, reduce postoperative pain and allow patients an earlier return to work. The article titled "Novel Drug Product to Improve Joint Motion and Function and Reduce Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction" appeared in the June 2008 edition of Arthroscopy: The Journal of Arthroscopic and Related Surgery.

The article reports on a prospective, double-blind, vehicle-controlled study of 30 evaluable patients undergoing arthroscopic allograft ACL reconstruction. Patients were randomized across two arms to receive either standard arthroscopic irrigation solution or the same solution with OMS103HP added to it. Patients were monitored for safety, and efficacy endpoints assessed over the 30-day postoperative period included measurements of knee function and motion, leg muscle strength, pain and return to work.

Results of the study demonstrated a statistically significant improvement in knee function, range of motion, quadriceps and hamstring muscle strength, pain management and return to work in OMS103HP-treated patients. The incidence of adverse events and abnormal clinical laboratory values for OMS103HP and the control arm were similar.

"We are pleased that Arthroscopy, a well-respected and peer-reviewed journal, chose to publish these clinical results obtained using OMS103HP, the most clinically advanced of our PharmacoSurgery product candidates," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "We look forward to completing our ongoing Phase 3 clinical program further evaluating the safety and efficacy of OMS103HP."

OMS103HP is a proprietary combination of active pharmaceutical ingredients with known anti-inflammatory, analgesic and vasoconstrictive activities. If approved, OMS103HP will be the first commercially available drug product for the improvement of function following arthroscopic surgery.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at http://www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... 2017 Pace Analytical, a company of over 2,000 employees and a ... acquired ESC Lab Sciences, further solidifying their position as the top American owned ... ... CEO of Pace Analytical ... of Mt Juliet, TN , enhances Pace Analytical,s capability as ...
(Date:6/30/2017)... 2017  AVACEN Medical (AVACEN) announced the publication of new research ... use of its AVACEN Treatment Method to significantly reduce ... ... Medical ... It affects approximately 200 to 400 million people worldwide according to ...
Breaking Medicine Technology:
(Date:7/20/2017)... Annapolis, MD (PRWEB) , ... July 20, 2017 ... ... Maryland company dedicated to the development of non-invasive devices and systems for monitoring ... $1.5 million. , Proceeds will be used to complete regulatory submissions and fund ...
(Date:7/20/2017)... ... July 20, 2017 , ... There’s a lot of ... and bulging discs are the same thing. But it’s crucial to understand both the ... proper treatment, according to Kaixuan Liu, MD, PhD, founder and president of Atlantic ...
(Date:7/20/2017)... ... July 19, 2017 , ... A local ... and increased funds raised to support fine arts programs in Chester County’s Elementary ... in Freed-Hardeman University’s Loyd Auditorium. , More than 850 people attended the ...
(Date:7/20/2017)... ... 2017 , ... Adolfson & Peterson Construction (AP) continues to ... a leader in healthcare construction, AP has successfully built several well-known medical facilities ... with Josh now on board. , Josh brings over nine years of ...
(Date:7/18/2017)... ... July 18, 2017 , ... CannaKids, a California Cooperative Cooperation ... announced today that at the WORLDZ Summit, taking place in Hollywood from July ... therapeutic benefits of medical cannabis for both pediatric and adult patients, and how the ...
Breaking Medicine News(10 mins):